Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Albert Bourla

Pfizer CEO tests positive for COVID-19, has mild symptoms

The top executive at Pfizer, a leading producer of COVID-19 vaccines, has tested positive for the virus and says he is experiencing very mild symptoms

The Independent UK

Watchdog reprimands EU executive for failing to share Von der Leyen texts

European Commission ‘gave no good reason’ why its president’s messages with Pfizer were not released

The Guardian - UK

How Pfizer won the pandemic, reaping outsize profit and influence

The grinding two-plus years of the pandemic have yielded outsize benefits for one company — Pfizer — making it both highly influential and hugely profitable as COVID-19 continues to infect tens of thousands of people and kill hundreds each day.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Malcolm Roberts says a rule change at the WHO 'would have decimated' Australia's sovereignty. Is he correct?

The One Nation senator has continued to push the baseless claim that Australia could be forced to adopt restrictive health measures by the World Health Organization.

ABC News

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

Pfizer Offers to Sell Medicines at Cost to Poorest Countries

US pharmaceutical giant Pfizer on Wednesday said it would sell its patented drugs on a not-for-profit basis to the world's poorest countries, as part of a new initiative announced at the World Economic Forum in Davos. "The time is now to begin closing this gap" between people with access to…

Asharq Al-Awsat

Pfizer To Sell 23 Patented Drugs, Vaccines At Lower Prices To Poorer Countries

Pfizer Inc (NYSE:PFE) will sell over 20 patent-protected drugs and vaccines at not-for-profit prices to 45 of the world's poorest countries. Under the program, Pfizer will begin shipping the medicines first to Ghana, Malawi, Rwanda, Senegal, and Uganda before the end of this year, Chief Executive Albert Bourla said in an interview. This will…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Cambodia, Laos to benefit as Pfizer slashes drug prices for poorest nations

Pfizer Inc plans to sell its entire portfolio of brand-name drugs at cost in as many as 45 lower-income countries, including Cambodia and Laos, one of the most comprehensive and ambitious drug-access programmes ever announced by a large pharmaceutical manufacturer.

Bangkok Post

Pfizer to sell all its patented drugs at nonprofit price in low-income countries

Pfizer Inc will make all of its patented medicines including COVID-19 treatment Paxlovid and big-selling breast cancer drug Ibrance available at a not-for-profit price to 45 of the world's poorest countries, the drugmaker said on Wednesday.

Reuters

Commentary: The US is doing too little to monitor Paxlovid use

Paxlovid, Pfizer’s antiviral treatment for COVID-19, is turning out to be one of the most successful new drugs in pharma history. Prescriptions have increased tenfold since February, and the five-day pill pack accounts for nearly 90% of the COVID-19 oral-antiviral market.

Tribune News Service

FDA Berates Pfizer CEO's Suggestion To Take More Paxlovid If COVID-19 Symptoms Rebound

The FDA berates Pfizer Inc (NYSE: PFE) CEO Albert Bourla's proposed solution in cases where virus levels rebound after the first course of treatment.

Benzinga

FDA contradicts Pfizer’s advice on 2nd course of COVID drug

There is “no evidence” that a second course of Pfizer Inc.’s Paxlovid will help COVID-19 patients whose symptoms return after an initial course of the antiviral, a U.S. Food and Drug Administration official said a day after Pfizer executives advocated the idea.

Tribune News Service

Parents of kids under 5 still waiting for COVID shots

The demise of the federal transportation mask mandate was particularly jarring for many parents of children under five anxiously waiting for word on when COVID shots will become available to their kids.

Axios

mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT

The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Salon

Pfizer CEO pushes yearly Covid shots

Assertions by pharmaceutical company executives have created pressure for scientists and politicians to take action

Tribune News Service

Pfizer CEO pushes yearly shots for COVID. Not so fast, experts say

When Pfizer CEO Albert Bourla said March 13 that all Americans would need a second booster shot, it struck many COVID-19 experts as a self-serving remark without scientific merit. It also set off spasms of doubt over the country’s objectives in its fight against the coronavirus.

Investors Business Daily

Vaccine Stocks Pfizer, Moderna Pop As 'Deltacron' Emerges, China Locks Down

Vaccine stocks popped Monday after Pfizer Chief Executive Albert Bourla said a fourth Covid shot is necessary "right now."

The Independent UK

Pfizer CEO says fourth vaccine dose will be needed

CDC only authorised third jab for most adults in the fall

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Fourth COVID shot will be ‘necessary,’ says Pfizer CEO

COVID-19 shots could soon become an annual item on your to-do list.

The Independent UK

Pfizer CEO claims Jared Kushner wanted to reroute vaccines from Canada and Latin America to US

‘Jared didn’t budge. In his mind, America was coming first no matter what,’ Albert Bourla writes

Bangkok Post

Pfizer sees Covid-19 drug sales topping $50bn in 2022

NEW YORK - Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its innoculation.

Al Jazeera

Pfizer CEO awarded $1M Genesis Prize for developing COVID vaccine

Albert Bourla is recognised for being at the forefront of fighting the pandemic and developing a vaccine in record time.

The Independent UK

Pfizer chief Albert Bourla wins $1 million Genesis Prize

Pfizer's chief executive, Albert Bourla, has been awarded the prestigious Genesis Prize for his efforts in leading the development of a COVID-19 vaccine

Salon

Four doses not enough to stop omicron

Omicron's vaccine-resistant properties have prompted Pfizer to start work on an omicron-specific vaccine

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.